Clinical Trial Update: Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

View source ↗

Summary

A real-world evidence study evaluating the incidence of retinal vasculitis in patients treated with aflibercept (Eylea) in the United States.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Vasculitis

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Retinal Vasculitis | Status: COMPLETED